Remedi Lists on Korea's Kosdaq on July 13 at 20,700 Won Per Share

According to Yonhapnews, portable X-ray device manufacturer Remedi debuted on South Korea's Kosdaq market on July 13 at 20,700 won per share, marking its successful listing after two previous failed attempts. The public offering recorded a competition ratio of 1,706:1.

Separately, H.L.G Genomics, a pharmaceutical raw material maker, launched public subscription for its Kosdaq listing on July 13–14, with pricing set at 21,500 won per share and a competition ratio of 714.5:1 among institutional investors. The company is scheduled to list on July 24.